Madrid

• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap … Ended recruitment
  2023-507772-50-00 5 2021-06-16 PSMA-positive metastatic castration-resistant prostate cancer
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended recruitment
  2023-508738-32-00 4 2021-06-16 Previously untreated and histologically confirmed HER2-Positive (HER2
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• Study of BGB-11417 in Patients with Mature B Cell Malignancies Ended recruitment
  2024-515592-35-00 1 2021-06-14 Mature B Cell Malignancies
• Rollover Study for Patients with Sickle Cell Disease who have Completed a prior Novartis-Sponsored Crizanlizumab Study Ended recruitment
  2024-510734-41-00 6 2021-06-10 Sickle cell disease
• A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended recruitment
  2024-516405-23-00 5 2021-06-08 Acute myeloid leukemia (AML) in second or later complete remission (CR
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive … Ended recruitment
  2023-505249-24-00 5 2021-05-27 HER2-positive metastatic breast cancer
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended recruitment
  2024-511753-22-00 5 2021-05-26 Primary Biliary Cholangitis
• Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal … Ended recruitment
  2024-514545-11-00 5 2021-05-26 Knee osteoarthritis
• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St … Ended recruitment
  2023-508372-10-00 4 2021-05-19 Non small Cell Lung cancer
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of … Ended recruitment
  2024-513227-16-00 5 2021-05-19 Immunoglobulin A Nephropathy (IgAN)
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended recruitment
  2023-509865-19-00 5 2021-04-30 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases. Ended recruitment
  2023-504419-34-00 4 2021-04-29 Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended recruitment
  2023-505615-21-00 5 2021-04-28 Muscle Invasive Bladder Cancer
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit … Ended recruitment
  2023-507274-40-00 3 2021-04-22 Myelofibrosis
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended recruitment
  2023-506525-11-00 5 2021-04-19 Primary Membranous Nephropathy (pMN)

Showing 2,305–2,328 of 3,550 trials